CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open
CSL Limited shares finished Friday’s session firmly higher, with the biotech giant benefiting from a broader rebound in Australian healthcare stocks and fresh attention on two CSL-specific threads: its ongoing on-market share buyback and the latest long-term durability data for its hemophilia B gene therapy, HEMGENIX. Market Index+2CSL Limited+2 Below is what happened after the bell on 12.12.2025, what the latest news and analysis dated 12.12.2025 is highlighting, and the key signals to monitor heading into the next session. (One calendar quirk first: 13.12.2025 is a Saturday, so the ASX isn’t open; the “next open” for ASX:CSL is the next